Skip to main content


  • Poster presentation
  • Open Access

The use of amisoulpride in alcoholic outpatients

  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Annals of General Psychiatry20087 (Suppl 1) :S305

  • Published:


  • Public Health
  • Alcohol
  • Diabetes Mellitus
  • Renal Failure
  • Gradual Increase


The goal of this study was to evaluate the effectiveness of amisoulpride (Solian) in chronic alcoholic patients and the registration of decrement of tendency to drink alcohol.

Materials and methods

33 patients (28 males and 5 females) who voluntarily came to the outpatient psychiatric department of our hospital with the request to break off abuse of alcohol were studied. Amisoulpride was given at dose 800 mg to all patients as the only treatment with gradual increase to 1200 mg. Our study involved patients with abuse of alcohol for longer than 2 years, aged 20-60 years. Patients with serious somatic problems (diabetes mellitus, chronic renal failure, liver disorder) were exempted. The effectiveness was evaluated after 1, 6 and 12 months of treatment.


Treatment with amisoulpride at dose 800 mg ?24h reduces significant the tendency of alcohol drinking in most of patients and that became more obvious 3 months later. The dose increased to 1200 mg for 8 patients because the results after 3 months of treatment were not significant. After 12 months of treatment, 29 patients cut off the abuse of alcohol and only 4 patients quit the treatment.


Administration of amisoulpride at dose 800-1200 mg to chronic alcoholic patients for 12 months causes gradual reduction of tedency to alcohol drinking.

Authors’ Affiliations

Psychiatric Clinic/General Hospital of Giannitsa, Giannitsa, Greece


  1. Mann K: Pharmacotherapy of alcohol dependence. CNS Drugs. 2004, 18: 485-504. 10.2165/00023210-200418080-00002.View ArticlePubMedGoogle Scholar
  2. Donata Marra: Amisulpride does not prevent relapse in primary alcohol dependence. Alcoholism:Clinical & Experimental Research. 26 (10): 1545-1552.Google Scholar


© Kalfas et al.; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.